ArticleGene therapy2010
Therapeutic potential of genetically modified adult stem cells for osteopenia.
Article in Gene therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis.Stem cell research & therapy · 2021Pooled it
- Growth Factor Gene-Modified Mesenchymal Stem Cells in Tissue Regeneration.Drug design, development and therapy · 2020Review
- Improved therapeutic potential of MSCs by genetic modification.Gene therapy · 2018Review
- One-Step Fabrication of Bone Morphogenetic Protein-2 Gene-Activated Porous Poly-L-Lactide Scaffold for Bone Induction.Molecular therapy. Methods & clinical development · 2017Article
- BMP2 gene delivery to bone mesenchymal stem cell by chitosan-g-PEI nonviral vector.Nanoscale research letters · 2015Article
- Gene therapy in India: a focus.Journal of biosciences · 2014Review
- A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus.Stem cells and development · 2012Article
- Mesenchymal stem cells as a novel vaccine platform.Frontiers in cellular and infection microbiology · 2012Article
- Differential mechanical response of mesenchymal stem cells and fibroblasts to tumor-secreted soluble factors.PloS one · 2012Article
- Genetic engineering of mesenchymal stem cells and its application in human disease therapy.Human gene therapy · 2010Review
- Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Chemistry and material science at the cell surface.Materials today (Kidlington, England) · 2010Article
- Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.The EPMA journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Adult stem cells have therapeutic potential because of their intrinsic capacity for self-renewal, especially for bone regeneration. The present study shows the utility of ex vivo modified mesenchymal stem cells (MSC) to enhance bone density in an immunocompetent mouse model of osteopenia. MSC were transduced ex vivo with a recombinant adeno-associated virus 2 (rAAV2) expressing bone morphogenetic protein 2 (BMP2) under the transcriptional control of collagen type-1alpha promoter. To enrich bone homing in vivo, we further modified the cells to transiently express the mouse alpha4 integrin. The modified MSC were systemically administered to ovariectomized, female C57BL/6 mice. Effects of the therapy were determined by dual-energy X-ray absorptiometry, 3D micro-CT, histology and immunohistochemistry for up to 6 months. Results indicated that mice transplanted with MSC expressing BMP2 showed significant increase in bone mineral density and bone mineral content (P < 0.001) with relatively better proliferative capabilities of bone marrow stromal cells and higher osteocompetent pool of cells compared to control animals. Micro-CT analysis of femora and other bone histomorphometric analyses indicated more trabecular bone following MSC-BMP2 therapy. Results obtained by transplanting genetically modified MSC from green fluorescent protein transgenic mouse suggested that production of BMP2 from transplanted MSC also influenced the mobilization of endogenous progenitors for new bone formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.